The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), today launched the Atopic Dermatitis and Vaccinia Network (ADVN), a nationwide research group that seeks to reduce the risk of eczema vaccinatum (EV), a severe and potentially deadly complication of smallpox immunization. EV occurs almost exclusively in people with a history of atopic dermatitis (AD), a chronic, itchy skin condition commonly referred to as eczema. While uncommon, EV can develop when AD patients are given the smallpox vaccine or come into close personal contact with people who recently received the vaccine. If untreated, EV can kill between 1 to 6 percent of those affected. In children younger than 2 years of age, EV has been estimated to kill up to 30 percent.
"Millions of Americans have a history of atopic dermatitis," says Anthony S. Fauci, M.D., director of NIAID. "Launching this network is an important step toward our goal of helping to protect everyone against the smallpox virus without the risk of life-threatening complications."
"Previous studies suggest that both innate and adaptive immunity are impaired in patients with atopic dermatitis, but the specific defects that increase the likelihood of eczema vaccinatum have yet to be explained," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "The information generated by this network will improve our understanding of the immune responses of these patients and should greatly influence the design of a safer smallpox vaccine."
The ADVN comprises three integrated components: a clinical studies consortium, an animal studies consortium and a statistical and data coordinating center.
The ADVN Clinical Studies Consortium will, among other activities, seek to understand why people with AD have such severe reactions to smallpox vaccine by evaluating their immune responses after natural exposure to less harmfPage: 1 2 Related medicine news :1
Contact: Paul Williams
NIH/National Institute of Allergy and Infectious Diseases
. NIAID initiates trial of experimental avian flu vaccine2
. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks3
. NIAID begins enrolling volunteers for novel HIV vaccine study4
. NIAID-sponsored clinical trial aims to boost flu vaccine supply5
. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks6
. NIAID launches influenza genome sequencing project7
. NIAID launches program to improve medical tools against emerging infectious diseases8
. NIAID rotavirus vaccine licensed for commercialization9
. Second NIAID SARS vaccine candidate helps mice fend off SARS10
. NIAID vaccine protects against SARS virus infection in mice11
. NIAID Ebola vaccine enters human trial